[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epithelial-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epithelial-ovarian-cancer":35},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,61,91,118,143,172,203,239,264,295,329,356,380,407,433,457,475,501,534,553,576,594,620,645,670],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":41,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100472291","a-study-comparing-perioperative-stress-reduction-vs-standard-of-care-in-ovarian-cancer-preserve-100472291",false,"NCT05429970","A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)","Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study","Inclusion Criteria:\n\n* Advanced (stage II-IV) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma diagnosed on the basis of imaging, CA125, and clinical assessment\n* Scheduled to undergo exploratory laparotomy and PDS or IDS\n* Scheduled for surgery with at least 10 days of lead time, to allow the participant to take the β-blocker and COX2 inhibitor 7 days preoperatively\n* Age ≥18 years\n* ASA score of 1 to 3\n* Ability to understand the study objectives and procedures, comply with the protocol, and provide informed consent\n\nExclusion Criteria:\n\n* Chronic treatment with any β-blocker or COX inhibitor\n* Contraindication for β-blocker therapy (asthma, second- or third-degree atrioventricular block, sinus bradycardia, sick sinus syndrome, right-sided heart failure, pheochromocytoma, peripheral vascular disease)\n* Contraindication for COX2 inhibitor therapy (renal failure \\[creatinine level \\>1.5 mg\u002FdL\\], significant liver failure \\[known cirrhosis, bilirubin level \\>2\\], active peptic disease), or current use of oral anticoagulant)\n* Contraindication for regional epidural anesthesia\n* Chronic autoimmune disease\n* Active infection\n* Pregnant\n* Minimally invasive procedure\n* Participation in another clinical trial that interferes with this study","FEMALE","18 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training\u002FMBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery\u002FPDS or IDS and also if it's better than the standard-of-care approach (no intervention for reducing stress).",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Ovarian Cancer","Ovarian Carcinoma","Stage II Ovary Cancer","Stage II Ovarian Cancer","Stage III Ovary Cancer","Stage III Ovarian Cancer","Stage IV Ovary Cancer","Stage IV Ovarian Cancer","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Stage II Fallopian Tube Cancer","Stage III Fallopian Tube Cancer","Stage IV Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[42,43,44,45,46,47,35,36,40],"ovarian cancer","propranolol","etodolac","MBRT","mind-body resilience training","music therapy","RECRUITING","2026-06-30",{"date":51,"type":52},"2026-07-01","ACTUAL",{"date":54,"type":52},"2022-06-17",{"date":56,"type":21},"2027-06-17",{"name":58,"class":59},"Memorial Sloan Kettering Cancer Center","OTHER",7,{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100644807","phase-1-immu-132-in-trop-2-overexpressed-advanced-and-relapsed-ovarian-cancer-100644807","NCT07674615","IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer","IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer: A Phases Ib, Single Arm Study","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years;\n* Histologically confirmed advanced or recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer;\n* Recurrent patients meeting one of the following two conditions:\n\nDisease recurrence or progression after at least one prior platinum-based chemotherapy regimen, with disease progression occurring less than 6 months from the last dose of platinum-based chemotherapy;\n\n* Disease recurrence or progression after at least three prior platinum-based chemotherapy regimens, with disease progression occurring ≥ 6 months from the last dose of platinum-based chemotherapy, and who are unable to receive standard platinum-based chemotherapy;\n* Patients with advanced epithelial ovarian cancer presenting with hematogenous metastasis, who are unable to receive standard treatment, with an estimated life expectancy of more than 3 months but approximately not exceeding 12 months with current therapy;\n* Have measurable disease per RECIST 1.1 criteria (Appendix A) or diagnosis of recurrence\u002Fdisease progression per GCIG criteria;\n* Known BRCA (Breast Cancer Gene) and HRD (Homologous Recombination Deficiency) status;\n* Have available paraffin-embedded or fresh tumor tissue for TROP-2 testing;\n* Tumor tissue TROP-2 H-score \\> 200;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;\n* Adequate bone marrow hematopoietic function and organ function, allowing the patient to receive treatment;\n* Patients must have had at least a 2-week interval from prior therapy (chemotherapy, investigational agents including small molecule inhibitors, endocrine therapy, immunotherapy, and\u002For radiotherapy) or major surgery;\n* Patients must have had at least a 2-week interval from high-dose systemic corticosteroids (however, low-dose corticosteroids \\\u003C 20 mg prednisone or its equivalent are permitted);\n* Patients must have recovered from acute toxicity due to prior therapy to Grade 1 or below;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients who have previously received topoisomerase I inhibitor therapy;\n* Patients with known hypersensitivity to the study drug, its metabolites, or formulation excipients;\n* Patients requiring ongoing treatment or prior use of any prohibited medications (e.g., UGT1A1 inhibitors);\n* Patients with Gilbert's syndrome;\n* Patients with other uncontrolled malignancies concurrently or within 5 years, whose treatment would interfere with the current therapy for recurrent ovarian cancer or affect the prognosis of this treatment. Carcinoma in situ and breast cancer (without active disease or signs of recurrence) are excluded;\n* Patients with a history of clinically significant hemorrhage, bowel obstruction, or gastrointestinal perforation within 6 months prior to the start of study treatment, with an estimated life expectancy of less than 3 months;\n* Patients with a history of significant cardiac disease within 6 months, such as uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure (NYHA Class III-IV), or clinically significant arrhythmias requiring antiarrhythmic therapy (except stable atrial fibrillation);\n* Patients with known clinically significant active chronic obstructive pulmonary disease (COPD) or other moderate-to-severe chronic respiratory disease within 6 months;\n* Patients with known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Patients with treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose, have all neurological symptoms returned to baseline, have no evidence of new or enlarging brain metastases, and are on a daily dose of ≤ 20 mg prednisone or its equivalent. All patients with carcinomatous meningitis are excluded regardless of clinical stability;\n* Patients with uncontrolled seizure history or active neurologic disorders; Patients with known HIV-1 or HIV-2 (or HIV-1\u002F2 antibody positive) with detectable viral load, or those taking medications that may interfere with SN-38 metabolism;\n* Patients with active HBV or HCV. For patients with a history of HBV or HCV, those with detectable viral load will be excluded;\n* Patients with known bleeding diathesis or active bleeding disorders;\n* Patients with active ≥ Grade 2 anorexia, nausea, or vomiting, and\u002For signs of bowel obstruction;\n* Patients with other concurrent medical or psychiatric conditions that, in the investigator's opinion, may confound study interpretation or prevent completion of study procedures and follow-up examinations;\n* Patients with any unstable medical problems (including the cardiac issues mentioned above, active treatment for symptomatic pulmonary embolism, stroke, renal or hepatic insufficiency, active infection\u002Fsepsis requiring intravenous antibiotics);\n* Any medical condition that, in the investigator's opinion, poses an undue risk to the patient's participation in the study.","80 Years",{"count":70,"type":21},19,[72],"PHASE1","To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.",[35,75,76,40],"Fallopian Tube Cancers","Primary",[78,79,80],"Ovarian cancer","TROP2","Antibody-drug conjugates","NOT_YET_RECRUITING","2026-06-28",{"date":49,"type":52},{"date":51,"type":21},{"date":86,"type":21},"2027-06-30",{"name":88,"class":89},"Shanghai Gynecologic Oncology Group","OTHER_GOV",1,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":98,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100634882","phase-3-a-study-comparing-bl-m07d1-with-physicians-choice-of-chemotherapy-in-patients-with-her2-expressing-platinum-resistant-recurrent-epithelial-ovarian-cancer-fallopian-tube-cancer-and-primary-peritoneal-cancer-100634882","NCT07545460","A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer","A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form and comply with the protocol requirements;\n2. Be ≥18 years and ≤75 years old on the day of signing the informed consent form;\n3. Have an expected survival time of ≥3 months;\n4. Have histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer;\n5. Have previously received a platinum-based regimen and have been confirmed to have platinum-resistant recurrence;\n6. Have received a total of ≥1 and ≤3 prior lines of therapy;\n7. If previously confirmed to be folate receptor alpha (FRα)-positive, must have received treatment with mirvetuximab soravtansine;\n8. Agree to provide archived tumor tissue specimens (from primary or metastatic lesions) collected within 3 years, or fresh tissue samples;\n9. Have at least one measurable lesion as defined by RECIST v1.1;\n10. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n11. Have recovered from toxicities of prior anti-tumor therapy to ≤ Grade 1 as defined by NCI-CTCAE v5.0;\n12. Have no severe cardiac dysfunction, with a left ventricular ejection fraction (LVEF) ≥50%;\n13. Meet the required organ function levels;\n14. For premenopausal women of childbearing potential, a serum pregnancy test must be performed within 7 days before starting treatment, with a negative result, and must not be breastfeeding; all enrolled patients must use adequate barrier contraception throughout the entire treatment period and for 6 months after treatment completion.\n\nExclusion Criteria:\n\n1. Received surgical treatment, radical radiotherapy, immunotherapy, etc. within 4 weeks before the first dose;\n2. Previously received ADC therapy with a topoisomerase I inhibitor as the payload, or HER2-ADC therapy;\n3. History of severe cardiovascular or cerebrovascular disease within six months before screening;\n4. Concurrent pulmonary disease resulting in severely impaired lung function;\n5. Prolonged QT interval, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias;\n6. Diagnosed with active malignancy within 3 years before study randomization;\n7. Unstable thrombotic event requiring therapeutic intervention within 6 months before screening;\n8. Hypertension inadequately controlled by two antihypertensive medications;\n9. Patients with poorly controlled blood glucose levels;\n10. History of ILD treated with steroids, or current ILD, or Grade ≥2 radiation pneumonitis, etc.;\n11. Patients with active central nervous system (CNS) metastases;\n12. Patients with a history of allergy to recombinant humanized antibodies or to any excipient of BL-M07D1;\n13. Prior receipt of organ transplantation or allogeneic hematopoietic stem cell transplantation;\n14. Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, or hepatitis C virus infection;\n15. Experienced severe infection within 4 weeks before the first dose of study drug;\n16. Presence of large serosal cavity effusions, or symptomatic serosal cavity effusions, etc.;\n17. Receiving long-term systemic corticosteroid therapy (e.g., \\>10 mg\u002Fday prednisone) prior to randomization;\n18. History of severe neurological or psychiatric disorders;\n19. Experienced serious non-healing wound, ulcer, or bone fracture within 4 weeks prior to signing informed consent;\n20. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent;\n21. Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.;\n22. Received other unapproved clinical study drugs or treatments within 4 weeks before study randomization;\n23. Subjects who plan to receive or have received a live vaccine within 28 days before the first dose;\n24. Presence of other serious physical conditions, abnormal laboratory findings, or poor compliance that may increase the risk of study participation, interfere with study results, or render the patient unsuitable for this study in the investigator's opinion.","ALL","75 Years",{"count":101,"type":21},404,[103],"PHASE3","This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.",[35,36,106],"Primary Peritoneal Cancer","2026-06-26",{"date":109,"type":52},"2026-06-29",{"date":111,"type":21},"2026-07",{"date":113,"type":21},"2028-12",{"name":115,"class":116},"Sichuan Baili Pharmaceutical Co., Ltd.","INDUSTRY",2,{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":90},"100545820","fasting-during-neoadjuvant-chemotherapy-in-patient-with-epithelial-ovarian-cancer-100545820","NCT06386887","Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer","The Feasibility, Safety, and Clinical Outcomes of Fasting During Neoadjuvant Chemotherapy in Patients With Epithelial Ovarian Cancer","Inclusion Criteria:\n\n* Age 18 years and above\n* Participants with confirmed diagnosis of primary epithelial ovarian cancer (EOC) by internal cytologic or histologic evaluation (including fallopian tube and primary peritoneal cancer)\n* Participants receiving platinum-based chemotherapy for ovarian cancer including\n\n  * Participants with stage III or IV EOC planned to undergo neoadjuvant chemotherapy (including participants who had a diagnostic laparoscopy or aborted debulking) OR\n  * Participants with stage III or IV EOC following primary debulking surgery\n  * Participants with recurrent epithelial ovarian cancer who will receive platinum-based chemotherapy OR\n  * Participants who had undergone neoadjuvant chemotherapy and interval debulking surgery who will be receiving adjuvant (postoperative) chemotherapy\n* Any invasive ovarian cancer histology\n* Normal cognitive function\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Malignant complete or partial bowel obstruction confirmed on imaging.\n* Participants unable to provide informed consent.\n* BMI \\\u003C18\n* Participants diagnosed with severe malnutrition as assessed by study dietitian\n* Type I diabetes on insulin\n* Absence of pretreatment CT abdomen and pelvis imaging or \\>4-6 weeks between imaging and cycle 1 of chemotherapy.",{"count":126,"type":21},20,[24],"The goal of this clinical trial is to see if timed fasting (periods of time that you don't eat) in participants who are receiving chemotherapy prior to surgery is achievable, safe and can improve quality of life, symptoms and outcomes (results) compared to participants who receive standard dietary recommendations in individuals being treated for epithelial ovarian cancer . The main questions it aims to answer are:\n\n* Is it feasible to use intermittent fasting during neoadjuvant chemotherapy?\n* Is it safe to use intermittent fasting during neoadjuvant chemotherapy?\n* Do participants find it acceptable to use intermittent fasting during neoadjuvant chemotherapy?\n\nResearchers will compare participants who receive standard dietary recommendations to see which method is more achievable, safe, and able to improve quality of life, symptoms and outcomes.\n\nParticipants will:\n\n* Receive either the fasting intervention (schedule of times when you do not eat) or standard diet recommendations for 6-9 weeks prior to your surgery starting with the second cycle of chemotherapy.\n* All participants will be asked to complete chemotherapy and surgery, cancer imaging, baseline screening tests, nutritional assessments, food diaries, blood tests, and surveys about wellbeing.\n* Participants in the intervention group will be asked to follow a fasting schedule that consists of not eating for 16 hours a day followed by normal eating for the remaining 8 hours of the day for 5 days in a row followed by 2 days of regular eating each week.",[35],[131,132,133,134],"Short term fasting","Intermittent fasting","Intermittent energy restriction (IER)","Fasting mimicking diet (FMD)","2026-06-24",{"date":137,"type":52},"2026-06-25",{"date":139,"type":52},"2024-07-11",{"date":51,"type":21},{"name":142,"class":59},"Case Comprehensive Cancer Center",{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":98,"minAge":18,"maxAge":68,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":160,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":90},"100626207","phase-1-18ffpyqcp-pet-imaging-of-fibroblast-activation-protein-in-selected-oncology-indications-100626207","NCT07432633","[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","A Phase 1\u002F2 Study of [18F]FPyQCP for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","Inclusion Criteria:\n\n1. Participants provide informed consent and confirm that they are able and willing to comply with all protocol requirements.\n2. Participants must be ≥ 18 years and \\\u003C 80 years of age and competent to give informed consent.\n3. Eastern Cooperative Oncology Group performance status ≤ 2.\n4. Diagnosis of either CRC (confirmed by histopathology), GC (confirmed by histopathology), PDAC (confirmed by cytology or histopathology), ILC (confirmed by histopathology), or EOC (suspected or confirmed by cytology or histopathology).\n5. Women of childbearing potential (WOCBP) should have a negative serum test at screening (Visit 1) and a negative urine pregnancy test at the PET\u002FCT imaging visit (Visit 2) prior to \\[18F\\]FPyQCP administration.\n6. WOCBP, and men who are sexually active with WOCBP, must agree to use a highly effective method(s) of contraception for the duration of the study\n7. Cohort A specific: Participants with stage I-III (see Appendix 3) CRC, GC, PDAC, ILC, or EOC (stage IV disease is allowed in the setting of oligometastatic disease \\[5 or fewer known metastases) as assessed by conventional imaging within 8 weeks of \\[18F\\]FPyQCP administration.\n8. Cohort B specific: Conventional imaging performed within 8 weeks of screening and no later than 24 hours before \\[18F\\]FPyQCP administration and available for upload to the central imaging vendor, including, at a minimum, a contrast-enhanced CT that includes the abdomen and pelvis.\n9. Either:\n\n   1. Treatment-naïve with at least stage IIB disease. Available biopsy sample or scheduled biopsy or surgical resection no later than Day 42.\n   2. Following neoadjuvant therapy (with at least stage IIB disease at initial presentation) with scheduled biopsy or surgical resection no later than Day 42. \\[18F\\]FPyQCP PET\u002FCT imaging should be performed as close to scheduled procedure as clinically feasible.\n   3. Suspected recurrence after definitive therapy\n\nExclusion Criteria:\n\n1. Participants administered any radioisotope within 5 physical half-lives prior to \\[18F\\]FPyQCP administration.\n2. Participants administered any other IMP within 2 weeks or 5 half-lives, whichever is longest, prior to \\[18F\\]FPyQCP administration.\n3. Participants who have recently received any other contrast agent (\\\u003C 24 hours for intravenous agents and \\\u003C 5 days for oral agents) before the day of \\[18F\\]FPyQCP administration.\n4. Participants with a history of severe claustrophobia or panic attacks when in confined spaces.\n5. Known hypersensitivity to \\[18F\\]FPyQCP or any of its constituents.\n6. Participants with any medical condition or other circumstances at screening or in their past medical history that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or study completion.\n7. Known diagnosis of an autoimmune or inflammatory disorder that is expected to confound image interpretation per investigator judgment, excluding disorders directly related to the index cancer (e.g. tumor-associated pancreatitis or biliary stasis for PDAC).\n8. Medical history of abdomino-pelvic or breast irradiation in the last 3 months.\n9. Presence of any current implanted foreign material (e.g. stents, surgical clips) that may confound image interpretation per investigator judgment.\n10. Significant renal or hepatic impairment.\n11. Female participants who are breastfeeding, unless the participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the \\[18F\\]FPyQCP administration.\n12. Cohort A Specific Exclusion Criteria: 12. No prior history of any other cancer, unless treated with curative-intent and disease-free for at least 5 years before Visit 1 (at least 1 year before Visit 1 for basal cell carcinoma, localized squamous cell carcinoma of the skin and in situ carcinoma of cervix).",{"count":151,"type":21},71,[72,153],"PHASE2","This is a multi-center, open-label, single-arm, Phase 1\u002F2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \\[18F\\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).",[156,35,157,158,159],"Colorectal Cancer","Gastric Cancer","Invasive Lobular Breast Carcinoma","Pancreatic Ductal Adenocarcinoma",[161,162],"Positron emission tomography","Fibroblast activation protein","2026-06-22",{"date":165,"type":52},"2026-06-23",{"date":167,"type":52},"2026-02-19",{"date":169,"type":21},"2028-01-31",{"name":171,"class":116},"Blue Earth Diagnostics",{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100584515","phase-2-a-study-to-assess-anti-tumor-activity-of-intravenously-iv-infused-carboplatin-with-mirvetuximab-soravtansine-in-participants-with-newly-diagnosed-folate-receptor-alpha-frexpressing-advanced-stage-serous-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer-100584515","NCT06890338","A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.","A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n* Be judged by the investigator and\u002For treating physician to be an appropriate candidate to receive neoadjuvant chemotherapy.\n* Diagnosis of biopsy-confirmed high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer.\n* Participant meets the following disease criteria:\n\n  * Stage III or IV disease by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging system, and\n  * Folate Receptor Alpha (FRα) expression positivity as defined by immunohistochemical staining of \\>= 75% of viable tumor cells with moderate \\>= 2+ membrane staining by the Ventana Folate Receptor Alpha (VENTANA FOLR1) assay, FOLR1 Eligibility Testing - Ventana FOLR1 (FOLR1-2.1) RxDx - Commercial or Central, and\n  * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.\n\nExclusion Criteria:\n\n* Endometrioid, clear cell, mucinous, or sarcomatous tumor histology; mixed tumors containing any of the above histologies; or low-grade\u002Fborderline ovarian tumor.\n* Previous clinical diagnosis of noninfectious interstitial lung disease, including noninfectious pneumonitis.\n* Previously treated with anticancer therapy including chemotherapy, radiation therapy, immunotherapy, or biologic agent for current cancer, with the exception of one cycle of single agent carboplatin\n* Participants with the following ocular history and\u002For concurrent disorders:\n\n  * History of corneal transplantation;\n  * Undergoing active postoperative management for refractive surgery, cataract surgery, corneal cross-linking, or corneal complications of surgery;\n  * Confluent superficial punctate keratopathy (SPK) not expected to resolve to non-confluence or better within the screening window with standard of care (SOC) intervention;\n  * Active or chronic clinically significant (\\>= Grade 3) corneal dystrophy (e.g., Fuchs dystrophy);\n  * Active ocular conditions requiring ongoing treatment\u002Fmonitoring, such as glaucoma, which is not adequately controlled with medication or surgery, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema or an ocular condition with high risk of retinal detachment;\n  * Monocular vision with visual acuity in the worse eye, worse than 20\u002F200 or visual fields less than 20 degrees (i.e., functional blindness in at least one eye).\n* History of other malignancy within 3 years prior to signing study consent. -- Note: Participants with tumors with a negligible risk for metastasis or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.",{"count":180,"type":21},140,[153],"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC).\n\nMirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States.\n\nParticipants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years .\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.",[35,36,106,184],"Neoadjuvant",[35,36,106,184,186,187,188,189,190,191,192],"Interval Debulking Surgery","Mirvetuximab Soravtansine","MIRV","IMGN853","ELAHERE(R)","Carboplatin","Bevacizumab","2026-06-15",{"date":195,"type":52},"2026-06-16",{"date":197,"type":52},"2025-11-21",{"date":199,"type":21},"2030-02",{"name":201,"class":116},"AbbVie",66,{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":98,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":224,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":238},"100574188","phase-1-ct-95-in-advanced-cancers-associated-with-mesothelin-expression-100574188","NCT06756035","CT-95 in Advanced Cancers Associated With Mesothelin Expression","Phase 1a\u002F1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression","Inclusion Criteria:\n\n* ECOG 0 or 1\n* Subjects with evaluable disease per RECIST 1.1 or mRECIST\n* Subjects with adequate organ function.\n* Subjects with advanced cancers associated with mesothelin expression\n\nExclusion Criteria:\n\n* Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.\n* Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy\n* Concurrent participation in another investigational clinical trial.\n* Evidence of leptomeningeal disease",{"count":211,"type":21},70,[72],"This is a Phase 1a\u002F1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.",[215,35,216,217,218,219,220,221,222,223,156],"Mesothelin-Expressing Tumors","Malignant Pleural Mesothelioma, Advanced","Malignant Peritoneal Mesothelioma, Advanced","Pancreatic Adenocarcinoma Advanced or Metastatic","Lung Adenocarcinoma Metastatic","Cholangiocarcinoma Advanced","Cholangiocarcinoma Non-resectable","Mesothelin-expressing Advanced Cancers","Mesothelin-positive Advanced Malignant Solid Tumors",[225,226,227,228,229],"Phase 1 Dose Escalation Study","CT-95","Advanced, recurrent cancers","Unresectable, metastatic cancers","Cancers associated with mesothelin expression","2026-06-10",{"date":232,"type":52},"2026-06-12",{"date":234,"type":52},"2025-03-31",{"date":113,"type":21},{"name":237,"class":116},"Context Therapeutics Inc.",9,{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":60},"100586411","phase-3-phase-3-trial-evaluating-the-safety--efficacy-of-imnn-001-administered-in-combination-w-standard-nact--adjuvant-chemotherapy-in-newly-diagnosed-patients-w-advanced-eoc-fallopian-tube-or-primary-peritoneal-cancer-100586411","NCT06915025","Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w\u002F Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w\u002F Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w\u002F Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w\u002F Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","OVATION-3","Inclusion Criteria:\n\n1. Participants must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.\n2. Participants with a histologically confirmed diagnosis of high-grade non-mucinous epithelial ovarian (serous, endometrioid, carcinosarcoma, mixed epithelial pathologies), fallopian tube or peritoneal cancer that is Stage IIIB\u002FC or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria.\n3. Participants eligible to receive neoadjuvant chemotherapy.\n4. Participants will provide a tumor tissue sample at pre-screening or screening, via laparoscopy or image guided core biopsy for determination of confirmed biomarker tumor status (HRD vs. HRP). See biomarker status definitions in the section below.\n5. Participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin) within 14 days prior to initiation of protocol therapy and be practicing an effective form of contraception. If applicable, participants must discontinue breastfeeding prior to study entry.\n6. Participants must have adequate:\n\n   1. Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500\u002Fµl. Exceptions may be made in patients with benign ethnic neutropenia \\>800\u002Ful with approval of a medical monitor. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. Platelets greater than or equal to 100,000\u002Fµl.\n   2. Renal function: eGFR \\> 60 ml\u002Fmin\u002F1.73m2\n   3. Hepatic function: Bilirubin ≤ 1.5 x ULN. SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN and alkaline phosphatase ≤ 2.5 x ULN. Exceptions due to hepatic metastases can be considered in consultation with medical monitor.\n   4. Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1 as defined by CTCAE version 5.0.\n7. Participants must have an ECOG score of 0, 1 or 2.\n8. Participants should be free of active infection requiring parenteral antibiotics or a serious uncontrolled medical illness or disorder within 4 weeks of study entry.\n9. Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to the first treatment. Continuation of hormone replacement therapy is permitted.\n\nExclusion Criteria:\n\n1. Participant who has received prior treatment with IMNN-001.\n2. Participant who has received oral or parenteral corticosteroids (\\>10 mg prednisone) within 2 weeks of first dose of IMNN-001 (if applicable) or who have a clinical requirement for ongoing systemic immunosuppressive therapy such as chronic steroid use not related to chemotherapy administration.\n3. Participant has mucinous, germ cell, transitional cell, clear cell, undifferentiated, or non-epithelial ovarian cancer.\n4. Participant has low-grade or Grade 1 epithelial ovarian cancer.\n5. Participant of childbearing potential, not practicing adequate contraception, participant who is pregnant, or participant who is breastfeeding are not eligible for this trial.\n6. Participant has a bowel obstruction by clinical symptoms or computed tomography (CT) scan, sub-occlusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.\n7. Participant has been diagnosed and\u002For treated with any therapy for invasive cancer \\\u003C3 years from study enrollment, completed adjuvant chemotherapy and\u002For targeted therapy at least 3 years from enrollment, or completed adjuvant hormonal therapy less than 4 weeks from enrollment.\n8. Participant with definitively treated non-invasive malignancies such as cervical carcinoma in situ, ductal carcinoma in situ, grade 1 or 2 Stage IA endometrioid endometrial cancer, or non-melanomatous skin cancer are allowed.\n9. Participant with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the participant to extreme risk or decreased life expectancy.\n10. Participant has known active hepatitis or HIV with detectable viral load.\n11. Participant has a known contraindication or uncontrolled hypersensitivity to the components of paclitaxel, carboplatin, IMNN-001, or their excipients.\n12. Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy).\n13. Participant is receiving treatment for active autoimmune disease. \"Active\" refers to any condition currently requiring therapy. Examples of autoimmune disease include systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.\n14. Participant who has received prior radiotherapy to any portion of the abdominal cavity or pelvis is excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed at least 3 years prior to registration, and the participant remains free of recurrent or metastatic disease.\n15. Participant who has received prior chemotherapy for any abdominal or pelvic tumor is excluded. Participant may have received prior adjuvant chemotherapy for localized breast cancer, if it was completed at least three years prior to registration, and that the participant remains free of recurrent or metastatic disease.\n16. Participant with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.\n17. Participant who will receive bevacizumab with the neoadjuvant or adjuvant treatment, or as maintenance will be excluded.\n18. Participant with any condition\u002Fanomaly that would interfere with the appropriate placement of the IP catheter for study drug administration including abdominal surgery within 4 weeks of study entry (for reason other than IP port placement or laparoscopic diagnosis of epithelial ovarian cancer), intestinal dysfunction as defined in #6 above.",{"count":248,"type":21},500,[103],"This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.",[35,27,36,40],[253,254,245],"IMNN-001","GEN-1","2026-06-01",{"date":257,"type":52},"2026-06-02",{"date":259,"type":52},"2025-07-09",{"date":261,"type":21},"2032-10-31",{"name":263,"class":116},"Imunon",{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":279,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":90},"100639206","phase-1-dual-targeting-car-nk-cells-for-recurrent-ovarian-cancer-msln-fr-muc16-pt2-100639206","NCT07617753","Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","A Phase 1\u002F2, Open-Label, Biomarker-Assigned Study of Dual-Targeting CAR-NK Cells Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα\u002FFOLR1), and\u002For MUC16 (CA125) in Patients With Recurrent or Refractory High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","DUAL-OV-CAR-NK","Inclusion Criteria:\n\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (high-grade serous preferred).\n* Recurrent or refractory disease after at least 2 prior systemic treatment lines (including a platinum-based regimen unless contraindicated).\n* Measurable disease per RECIST v1.1.\n* Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125) (archival or fresh biopsy).\n* ECOG performance status 0-1.\n* Adequate organ function : ANC \\>= 1.0 x 10\\^9\u002FL; platelets \\>= 75 x 10\\^9\u002FL; hemoglobin \\>= 8 g\u002FdL; AST\u002FALT \\\u003C= 3 x ULN (\\\u003C= 5 x ULN with liver metastases); total bilirubin \\\u003C= 1.5 x ULN; creatinine clearance \\>= 50 mL\u002Fmin.\n* Negative pregnancy test for women of childbearing potential; agreement to use effective contraception through 12 months post-infusion (or per local gene-therapy guidance).\n* Able to comply with study procedures and follow-up schedule; written informed consent.\n\nExclusion Criteria:\n\n* Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or any prior therapy directed to the same target, per protocol).\n* Active central nervous system (CNS) metastases or carcinomatous meningitis requiring therapy.\n* Uncontrolled infection, including active tuberculosis; or clinically significant, uncontrolled viral infection.\n* Known HIV infection with uncontrolled viremia; active hepatitis B or hepatitis C with detectable viral load (testing required at screening).\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA Class III\u002FIV heart failure).\n* Active autoimmune disease requiring systemic immunosuppression within 30 days (physiologic steroid replacement allowed).\n* Concurrent anti-cancer therapy (chemotherapy, targeted therapy, radiotherapy) not permitted within a protocol-defined washout period.\n* Major surgery within 4 weeks prior to lymphodepletion (except minor procedures)\n* Pregnant or breastfeeding.\n* Any condition that, in the investigator's judgment, would increase risk (e.g., severe pulmonary disease) or interfere with study interpretation.",{"count":273,"type":21},36,[72,153],"This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha\u002FFOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.",[35,40,277,278],"Fallopian Tube Carcinoma","Recurrent or Refractory Disease After Standard Therapies",[280,281,282,283,284,285,286,78],"CAR-NK","Dual targeting","Mesothelin (MSLN)","Folate Receptor alpha","MUC16","Intraperitoneal administration","Adoptive cell therapy","2026-05-25",{"date":255,"type":52},{"date":290,"type":52},"2026-03-02",{"date":292,"type":21},"2028-03-17",{"name":294,"class":116},"Beijing Biotech",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":4},"100638290","phase-2-liposomal-irinotecan-plus-enlonstobart-for-platinum-resistant-recurrent-ovarian-cancer-100638290","NCT07591831","Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer","An Exploratory Clinical Study of Liposomal Irinotecan Combined With Enlonstobart in Patients With Platinum-Resistant Recurrent Ovarian Cancer","Inclusion Criteria:\n\n1. Female participants aged 18 to 75 years, inclusive, at the time of signing informed consent.\n2. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, FIGO stage II-IV.\n3. Platinum-resistant recurrent disease, defined as disease progression within 6 months after the last platinum-containing chemotherapy, and not platinum-refractory disease, defined as disease progression within 4 weeks after initial platinum-containing chemotherapy. Participants may have received up to two prior lines of non-platinum systemic therapy. Treatment with a PARP inhibitor or anti-angiogenic therapy after platinum-resistant recurrence will be counted as one line of therapy; maintenance treatment with a PARP inhibitor or anti-angiogenic therapy will not be counted as a treatment line.\n4. Ability to provide sufficient qualified formalin-fixed paraffin-embedded tumor tissue samples or slides for PD-L1 testing. Participants who are unable to provide tumor tissue slides for certain reasons may be enrolled at the investigator's discretion.\n5. At least one measurable lesion at baseline according to RECIST version 1.1. The measurable lesion must not have received prior local therapy such as radiotherapy. A lesion located within a previously irradiated area may be selected as a target lesion if disease progression has been confirmed.\n6. ECOG performance status of 0 or 1.\n7. Expected survival of at least 3 months.\n8. Adequate organ function, meeting all of the following criteria without blood transfusion, hematopoietic stimulating factors, or medication correction of blood cell counts within 14 days before the first dose:\n\n   1. Absolute neutrophil count ≥1.5 × 10\\^9\u002FL;\n   2. Platelet count ≥75 × 10\\^9\u002FL;\n   3. Hemoglobin ≥9 g\u002FdL;\n   4. Serum creatinine ≤1.5 × the upper limit of normal or creatinine clearance ≥50 mL\u002Fmin;\n   5. Total bilirubin ≤1.5 × the upper limit of normal, or ≤3 × the upper limit of normal for participants with Gilbert's syndrome;\n   6. Alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal, or ≤5 × the upper limit of normal for participants with liver metastases;\n   7. Activated partial thromboplastin time and international normalized ratio ≤1.5 × the upper limit of normal, without anticoagulants or other drugs affecting coagulation function within 14 days before the first dose, except for participants requiring long-term anticoagulation due to underlying disease.\n9. Toxicities caused by prior antitumor therapy must have recovered to Grade 1 or lower according to CTCAE version 5.0, except for residual alopecia and fatigue.\n10. Participants must understand the study and voluntarily sign written informed consent before study entry.\n\nExclusion Criteria:\n\n1. History of severe hypersensitivity reaction to monoclonal antibody preparations or uncontrolled allergic asthma.\n2. Known untreated central nervous system metastases, or treated but still symptomatic central nervous system metastases. Participants with residual signs or symptoms related to central nervous system treatment may be eligible if neurological symptoms have been stable or improved for at least 2 weeks before screening.\n3. History of primary immunodeficiency.\n4. Active autoimmune disease or history of autoimmune disease. Participants with well-controlled type 1 diabetes mellitus, well-controlled hypothyroidism requiring only hormone replacement therapy, skin diseases not requiring systemic treatment such as vitiligo, psoriasis, or alopecia, or conditions not expected to recur without external triggers may be eligible for further screening.\n5. Serious arterial or venous thrombotic events within 3 months before screening, such as transient ischemic attack, cerebral hemorrhage, cerebral infarction, deep venous thrombosis, or pulmonary embolism.\n6. History of interstitial lung disease, except localized radiation-induced interstitial pneumonia, or noninfectious pneumonia requiring glucocorticoid therapy.\n7. Prior treatment with any antibody or drug targeting T-cell costimulatory or immune checkpoint pathways, including PD-1, PD-L1, PD-L2, CTLA-4, OX40, or CD137 inhibitors.\n8. Prior immune-related adverse event of CTCAE version 5.0 Grade 3 or higher after immunotherapy.\n9. Major surgery or radical radiotherapy within 28 days before the first dose; palliative radiotherapy within 14 days before the first dose; or use of radiopharmaceuticals such as strontium or samarium within 56 days before the first dose.\n10. Systemic antitumor therapy within 28 days before the first dose, including but not limited to chemotherapy, immunotherapy, macromolecular targeted therapy, or biological therapy such as tumor vaccines, cytokines, or growth factors used to control cancer. Small-molecule targeted therapy or oral fluoropyrimidines within 14 days before the first dose or within 5 half-lives, whichever is longer; or mitomycin C or nitrosoureas within 6 weeks before the first dose.\n11. Receipt of a live attenuated vaccine within 28 days before the first dose or planned receipt of a live attenuated vaccine during the study.\n12. Any active infection requiring systemic treatment by intravenous infusion within 28 days before the first dose.\n13. Treatment within 14 days before the first dose with traditional Chinese patent medicines approved by the NMPA whose package inserts clearly state antitumor indications, or traditional Chinese herbal medicine documented in the medical record as being used for antitumor purposes.\n14. Whole blood or blood component transfusion within 14 days before the first dose.\n15. Treatment with glucocorticoids equivalent to prednisone \\>10 mg\u002Fday or other immunosuppressive agents within 14 days before the first dose.\n16. Participation in another clinical trial and receipt of investigational treatment within 28 days before the first dose, calculated from the date of the last treatment in the previous clinical study, except participation in overall survival follow-up of a study.\n17. Positive human immunodeficiency virus antibody or Treponema pallidum antibody; positive hepatitis B surface antigen and\u002For hepatitis B core antibody with hepatitis B virus DNA above the upper limit of normal of the testing laboratory; or positive hepatitis C antibody with hepatitis C virus RNA above the upper limit of normal of the testing laboratory.\n18. History of active tuberculosis.\n19. Pregnancy or breastfeeding.\n20. Other malignancy that progressed or required treatment within 5 years before screening, except adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or cured carcinoma in situ such as breast carcinoma in situ.\n21. Any other condition that may increase the risk associated with study treatment, interfere with interpretation of study results, affect study compliance, or otherwise make the participant unsuitable for the study in the investigator's judgment.\n22. Any clinically significant gastrointestinal disease, including liver disease, bleeding, inflammation, obstruction, or diarrhea greater than Grade 2.\n23. Current use or use within the past 2 weeks of strong CYP3A enzyme inducers or inhibitors and\u002For strong UGT1A inhibitors.\n24. Prior use of liposomal irinotecan formulation or irinotecan.\n25. Any condition that, in the investigator's judgment, makes the participant unsuitable for this study.",{"count":303,"type":21},30,[153],"This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian cancer.\n\nEligible female participants with histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, FIGO stage II-IV, will receive liposomal irinotecan and enlonstobart every 2 weeks. Tumor assessment will be performed every 8 weeks. Participants may discontinue study treatment in the event of disease progression, intolerable toxicity, withdrawal of consent, or other reasons judged by the investigator.",[307,75,35,106],"Platinum-resistant Recurrent Ovarian Cancer",[309,310,311,312,313,314,315,316,317,318,319],"Platinum-resistant ovarian cancer","Recurrent ovarian cancer","Epithelial ovarian cancer","Fallopian tube cancer","Primary peritoneal cancer","Liposomal irinotecan","Enlonstobart","PD-1 inhibitor","Objective response rate","Progression-free survival","Overall survival","2026-05-15",{"date":322,"type":52},"2026-05-18",{"date":324,"type":21},"2026-05-30",{"date":326,"type":21},"2030-05-30",{"name":328,"class":59},"Tianjin Medical University Cancer Institute and Hospital",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":90},"100539550","phase-1-autologous-car-t-cells-targeting-b7h3-in-ovarian-cancer-ic9-carb7-h3-t-cells-100539550","NCT06305299","Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells","Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects With Recurrent Platinum Resistant Epithelial Ovarian Cancer","Inclusion Criteria:\n\n1. Unless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study:\n2. Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information explained to, understood by and signed by the subject.\n3. Age ≥ 18 years at the time of consent.\n4. Eastern Cooperative Oncology Group (ECOG) of 0-2.\n5. The subject must have histologically or cytologically confirmed epithelial ovarian, peritoneal or fallopian tube cancer and must have a histological diagnosis of a high-grade serous histology based on local histopathological findings.\n6. Subject must have recurrent platinum-resistant or platinum-refractory disease defined as: A disease that has progressed by imagining while receiving platinum OR Disease that has recurred within 6 months of the last receipt of platinum-based chemotherapy. Rising CA-125 only is not considered as platinum-resistant or refractory disease.\n7. Having received at least 2 prior regimens (including front-line therapy).\n\nExclusion Criteria:\n\n1. Subjects with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n2. The subject is not willing and not able to comply with study procedures based on the judgment of the investigator or protocol designee.\n\n10\\. The subject is not willing to undergo a biopsy prior to treatment, after infusion, and at the time of disease progression ), and the tumor is determined to be safe by the treating investigator for biopsy collection.",{"count":337,"type":21},27,[72],"The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. The study team wants to know how much (dose) of the iC9-CAR.B7-H3 T cells are safe to use in patients without causing too many side effects and what is the maximum dose could be tolerated.\n\nThere are two parts to this study. In part 1, approximately blood will be collected from subjects to prepare the iC9.CAR.B7-H3 T cells. The study team will collect disease-fighting T cells from the blood and modify them to prepare the iC9.CAR.B7-H3 T cells. In part 2, the iC9.CAR.B7-H3 T cells will be given to eligible subjects by infusion three days after completion of lymphodepletion chemotherapy.",[341,27,35,342],"Ovary Neoplasm","Recurrent",[344,345,346],"cellular therapy","biologic therapy","Platinum Resistant","2026-05-14",{"date":349,"type":52},"2026-05-19",{"date":351,"type":52},"2024-07-29",{"date":353,"type":21},"2036-04",{"name":355,"class":59},"UNC Lineberger Comprehensive Cancer Center",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":368,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100638683","sentinel-lymph-node-mapping-in-early-stage-epithelial-ovarian-cancer-surgery-100638683","NCT07593339","Sentinel Lymph Node Mapping in Early-Stage Epithelial Ovarian Cancer Surgery","Feasibility and Evaluation of Sentinel Lymph Node Mapping in Early-Stage Epithelial Ovarian Cancer Surgery: A Tertiary Center Prospective Cohort Study","Inclusion Criteria:\n\n* Female patients aged 18-90 years\n* Patients undergoing laparotomy for unilateral or bilateral adnexal mass\n* Intraoperative frozen section diagnosis of malignant epithelial ovarian tumor or at least borderline epithelial tumor\n* Patients with bilateral adnexal masses who have undergone preoperative gastrointestinal evaluation (endoscopy\u002Fcolonoscopy) with exclusion of gastrointestinal malignancies\n* Patients without radiological evidence of advanced-stage ovarian cancer on preoperative imaging (PET, MRI, or CT), including absence of pleural effusion, omental cake, peritoneal carcinomatosis, malignant ascites, liver or splenic parenchymal involvement, and mesenteric involvement\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Patients with prior lymphadenectomy\n* Patients with radiological or intraoperative evidence of advanced-stage ovarian cancer\n* Patients planned for neoadjuvant chemotherapy without primary surgery\n* Pregnant patients\n* Patients with known allergy to indocyanine green (ICG) or iodine\n* Patients with immunodeficiency disorders\n* Patients with a history of radiotherapy\n* Patients with a history of vascular surgery affecting lymphatic drainage\n* Patients with a history of vascular surgery affecting lymphatic drainage\n* Patients with a history of non-gynecological malignancy\n* Patients younger than 18 years or older than 90 years","90 Years",{"count":303,"type":21},[24],"This prospective study aims to evaluate the feasibility and diagnostic performance of sentinel lymph node (SLN) mapping using indocyanine green (ICG) in patients undergoing surgery for early-stage epithelial ovarian cancer. Ovarian cancer is the most lethal gynecologic malignancy, and although systematic pelvic and paraaortic lymphadenectomy is considered a standard component of surgical staging. Moreover, systematic lymphadenectomy is associated with increased operative time, perioperative morbidity, and long-term complications such as lymphedema, without clear evidence of therapeutic benefit.\n\nSLN mapping has been successfully implemented in other gynecologic malignancies and may provide a less invasive alternative for lymph node assessment. In this study, patients undergoing laparotomy for adnexal masses will receive intraoperative ICG injection into the infundibulopelvic ligament on the affected side and into the cervix (at the 3 and 9 o'clock positions) following intraoperative confirmation of malignant epithelial tumor by frozen section analysis. SLN detection rates, anatomical distribution, and feasibility will be assessed. In addition, intraoperative and postoperative outcomes and potential complications related to the procedure will be evaluated.\n\nThe results of this study are expected to contribute to the current evidence regarding the role of SLN mapping in early-stage epithelial ovarian cancer and may help reduce the need for systematic lymphadenectomy and its associated morbidity.",[35],[369,370,27,371,372],"Sentinel Lymph Node","Indocyanine Green","Surgical Staging","Sentinel Lymph Node Mapping","2026-05-12",{"date":322,"type":52},{"date":255,"type":21},{"date":377,"type":21},"2028-03-01",{"name":379,"class":89},"Başakşehir Çam & Sakura City Hospital",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":405,"leadSponsor":406,"locationsCount":90},"100638813","phase-1-dual-target-car-nk-cells-in-recurrent-or-refractory-epithelial-ovarian-cancer-100638813","NCT07589543","Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","A Phase 1\u002F2, Open-Label, Dose-Escalation and Expansion Study of Dual-Target CAR-NK Cells (EB-DUALNK) Following Lymphodepleting Chemotherapy in Adults With Recurrent or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma","EB-DUALNK-OV","Inclusion Criteria:\n\n* Age 18-75 years; able to provide written informed consent.\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma that is recurrent or refractory after standard therapy (at least 2 prior systemic regimens), with measurable disease per RECIST v1.1 and ECOG performance status 0-1.\n* Tumor tissue available for antigen assessment. Participant must meet protocol-defined positivity for the selected dual-target pair (example: 1 target expressed in \\>=50% of tumor cells by IHC and the second target in \\>=20%).\n* Adequate organ function per protocol-specified labs; negative pregnancy test nd agrees to use effective contraception for a protocol-defined period after infusion.\n\nExclusion Criteria:\n\n* Active CNS metastases or carcinomatous meningitis (unless treated and stable for a protocol-defined period).\n* Prior gene-modified cell therapy targeting any of the study antigens (GD2, MUC1, PSMA, mesothelin) within 6 months.\n* Uncontrolled active infection (including uncontrolled HIV, HBV, or HCV) or active systemic fungal infection.\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, unstable angina, uncontrolled arrhythmia) or LVEF \\\u003C50% .\n* Active autoimmune disease requiring systemic immunosuppression within 14 days prior to lymphodepletion (physiologic steroid replacement permitted).\n* History of organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Pregnant or breastfeeding.\n* Any condition that, in the investigator's judgment, would compromise participant safety or compliance.",{"count":389,"type":21},42,[72,153],"This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial ovarian cancer. Candidates for targeting include GD2, MUC1, PSMA, and mesothelin. After baseline biomarker assessment (tumor antigen expression), the program will select the most suitable dual-target pair for clinical testing. Participants will receive lymphodepleting chemotherapy followed by EB-DUALNK infusion and safety\u002Fresponse follow-up.",[35,393],"Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum",[395,78,396,286,280,397,398,399,400,401],"Solid tumor","Immunotherapy","Dual-target","GD2","MUC1","PSMA","Mesothelin","2026-05-10",{"date":320,"type":52},{"date":290,"type":52},{"date":292,"type":21},{"name":294,"class":116},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":432},"100461124","phase-2-tinzaparin-and-biomarkers-after-neoadjuvant-treatment-of-ovarian-cancer-100461124","NCT05284552","Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","The Effect of Tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy - A Randomized Pilot Study","Inclusion Criteria:\n\n* The subject has given written consent to participate in the study.\n* Age 18 and above\n* Epithelial ovarian, fallopian tube or peritoneal cancer, or abdominal cancer where a biopsy indicates an origin from the ovary, fallopian tube or peritoneum.\n* Histology diagnosis of either high grade serous carcinoma, endometroid carcinoma or clear cell carcinoma.\n* FIGO stage III-IV disease.\n* Planned for platinum-based chemotherapy\n* Prior to start of NACT pregnancy should be ruled out by menstrual history or in unclear cases by a urine hCG test.\n* Women of childbearing potential should use a safe birth control method (combined hormonal contraception, progesterone only hormonal contraception, intra uterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence, male or female condom, diaphragm with spermicide).\n* WHO Performance Status 0-2\n* Weight 50-150 kg\n* CA-125-level ≥250 kIE\u002FL at diagnosis\n\nExclusion Criteria:\n\n* Concomitant treatment with heparins, low molecular weight heparins, warfarin or non-vitamin K antagonist oral anticoagulants. Platelet inhibitors are allowed.\n* Treatment with heparins, low molecular weight heparins or non-vitamin K antagonist oral anticoagulants within the last year.\n* Known or suspected allergies against any product included in the study\n* Ongoing pregnancy, independent of gestational age. Breastfeeding or planned pregnancy\n* EOC disclosed at Cesarean section\n* Abdominal surgery or other major surgery within the last year\n* Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation\n* Treatment or disease which, according to the investigator, can affect treatment or study results\n* Known brain metastasis\n* Participation or recent participation (within the last 30 days) in a clinical study with an investigational product\n* Ongoing treatment of thromboembolic disease.\n* Thromboembolic disease within the last year.\n* Hypersensitivity to the active substance (tinzaparin) or any of the excipients.\n* Serious hemorrhage or conditions predisposing to serious hemorrhage. Serious hemorrhage is defined as fulfilling any one of these three criteria:\n\n  1. occurs in a critical area or organ (e.g. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, intra-uterine or intramuscular with compartment syndrome),\n  2. causes a fall in hemoglobin level of 20 g\u002FL (1.24 mmol\u002FL) or more, or\n  3. leads to transfusion of two or more units of whole blood or red blood cells.\n* Severe coagulation disorder.\n* Acute gastro duodenal ulcer.\n* Septic endocarditis.\n* Previous heparin-induced thrombocytopenia.\n* WHO Performance Status \\>2.\n* E-GFR \\\u003C30ml\u002Fmin (analyzed no more than 14 days before start of treatment with investigational product)\n* Platelets \\\u003C100 x10\\^9\u002FL (analyzed no more than 14 days before start of treatment with investigational product)\n* Treatment for other known malignancy within the last year (except basal cell carcinoma)",{"count":415,"type":21},40,[153],"Background:\n\nPrevious findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC).\n\nStudy objectives:\n\nPrimary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (NACT).\n\nSecondary objectives: The secondary objective of the study is to explore the impact of tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse events caused by tinzaparin will be described.",[35],[420,421,422],"Tinzaparin","Neoadjuvant chemotherapy","FIGO stage III-IV","2026-05-06",{"date":425,"type":52},"2026-05-11",{"date":427,"type":52},"2022-07-12",{"date":429,"type":21},"2027-12",{"name":431,"class":59},"University Hospital, Linkoeping",8,{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":98,"minAge":18,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":432},"100616306","phase-2-a-study-of-isoquercetin-in-people-with-ovarian-cancer-100616306","NCT07303894","A Study of Isoquercetin in People With Ovarian Cancer","Randomized, Multi-dose, Placebo-controlled Phase 2 Trial of Oral Isoquercetin to Reduce Thrombin Generation in Ovarian Cancer","Inclusion Criteria:\n\n* Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with day 1 of cycle 1 or 2 of chemotherapy) for neoadjuvant, adjuvant, or advanced settings.\n* Minimum age 18 years\n* Life expectancy of greater than 6 months.\n* ECOG performance status \\\u003C2\n* Participants must have preserved organ and marrow function as defined below:\n\n  * Platelet count \\> 50,000\u002FmcL\n  * Prothrombin time (PT) and partial thromboplastin time (PTT) \\\u003C 1.5 x institutional upper limit of normal (ULN)\n  * Total bilirubin \\\u003C 3 x ULN without liver metastases and \\\u003C5 x ULN in presence of liver metastases.\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 3 X ULN without liver metastases and \\\u003C5 x ULN in the presence of liver metastases.\n  * Estimated creatinine clearance (CrCl \\>30 ml\u002Fmin)\n* The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior history of documented venous thromboembolic event within the last 2 years (excluding central line associated events whereby patients completed anticoagulation)\n* Active bleeding or high risk for bleeding (e.g., known acute gastrointestinal ulcer)\n* History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months\n* Familial bleeding diathesis\n* Known diagnosis of disseminated intravascular coagulation (DIC)\n* Currently receiving anticoagulant therapy\n* Current daily use of aspirin, clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen \\> 800 mg daily or equivalent)\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Known intolerance of (iso)quercetin, niacin or ascorbic acid (including known G6PD deficiency).\n* Participants with known brain metastases\n* Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin.",{"count":441,"type":21},90,[153],"The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.",[27,35,445],"Serous Ovarian Tumor",[27,35,445,447,58,448],"Isoquercetin","25-060","2026-04-15",{"date":451,"type":52},"2026-04-16",{"date":453,"type":52},"2026-01-22",{"date":455,"type":21},"2032-01",{"name":58,"class":59},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":98,"minAge":18,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":474,"locationsCount":90},"100592497","phase-3-a-study-comparing-bl-b01d1-with-the-investigators-choice-of-chemotherapy-in-patients-with-platinum-resistant-recurrent-epithelial-ovarian-cancerpanku-gyn01-100592497","NCT06994195","A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)","A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form and comply with the protocol requirements;\n2. Age: ≥18 years old;\n3. Expected survival time ≥3 months;\n4. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer;\n5. Previously treated with a platinum-based regimen and confirmed to have platinum-resistant recurrence;\n6. Previously received 1-3 lines of systemic anti-tumor therapy, with radiographic evidence of disease progression during or after the last line of treatment or intolerance to the current treatment prior to randomization;\n7. For subjects with documented folate receptor-alpha (FRα) positivity, progression must have occurred after treatment with mirvetuximab soravtansine;\n8. Agree to provide archived tumor tissue specimens or fresh tissue samples from the primary or metastatic lesions within the past 3 years;\n9. Must have at least one measurable lesion as defined by RECIST v1.1;\n10. ECOG performance status score of 0 or 1;\n11. Toxicity from prior anti-tumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;\n12. No severe cardiac dysfunction, with left ventricular ejection fraction ≥50%;\n13. Organ function levels must meet the requirements;\n14. Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n15. For premenopausal women with childbearing potential, a serum pregnancy test must be performed within 7 days before starting treatment, and the result must be negative; they must not be breastfeeding. All enrolled patients should use adequate barrier contraception throughout the treatment period and for 6 months after treatment ends.\n\nExclusion Criteria:\n\n1. Use of chemotherapy, targeted therapy, biologic therapy, etc., within 4 weeks or 5 half-lives prior to study randomization and palliative radiotherapy, etc., within 2 weeks;\n2. Patients with locally advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer who are eligible for radical locoregional therapy;\n3. Front line received ADCs targeting topoisomerase I inhibitors or EGFR and\u002For HER3;\n4. History of severe heart disease and cerebrovascular disease;\n5. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;\n6. Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n7. Diagnosed with active malignancy within 3 years before randomization;\n8. Hypertension poorly controlled by two antihypertensive drugs;\n9. Patients with poor glycemic control;\n10. Patients with grade ≥1 radiation pneumonitis according to the RTOG\u002FEORTC definition; Previous history of ILD;\n11. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;\n12. Patients with active central nervous system metastases;\n13. Severe infection occurred within 4 weeks before randomization in study 13; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;\n14. Patients with massive or symptomatic effusions or poorly controlled effusions;\n15. Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;\n16. Serious unhealed wound, ulcer or fracture within 4 weeks before signing the informed consent;\n17. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n18. Patients with inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;\n19. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;\n20. Had a history of autologous or allogeneic stem cell transplantation;\n21. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;\n22. A history of severe neurological or psychiatric illness;\n23. Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;\n24. Subjects who were scheduled to be vaccinated or received live vaccine within 28 days before study randomization;\n25. Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.",{"count":465,"type":21},384,[103],"This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.",[35,36,106],{"date":470,"type":52},"2026-04-20",{"date":472,"type":52},"2025-08-04",{"date":429,"type":21},{"name":115,"class":116},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":490,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":500},"100402145","phase-1-a-study-of-azenosertib-zn-c3-in-patients-with-ovarian-cancer-100402145","NCT04516447","A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer","A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer","MUIR","INCLUSION CRITERIA:\n\nFor Part 1:\n\n* Histologically or cytologically confirmed FIGO Stage III\u002FIV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal carcinoma.\n* Subjects must have received 1 or 2 prior therapeutic regimens\u002Flines of therapy in the advanced or metastatic setting. At least one regimen must have contained cisplatin or carboplatin.\n* The disease must be platinum resistant (ie, the PFI must have been \\\u003C 6 months). Platinum refractory disease (ie, PD during first-line platinum-based therapy) is allowed.\n\nFor Part 2 Dose Escalation:\n\nPrior therapy:\n\n• Subjects must have received 6 cycles of platinum-based doublet chemotherapy in the 1L or 2L setting as their most recent therapy\n\nResponse to prior platinum therapy:\n\n1. In the 1L setting: Complete Response, Partial Response, or Stable Disease to platinum-based chemotherapy.\n2. In the 2L setting:\n\n   1. Progressive Disease \\>183 days after receiving the last dose of platinum chemotherapy in the 1L setting,\n   2. Complete Response, Partial Response, or Stable Disease to 2L platinum-based chemotherapy.\n\n      * Adequate hematologic, and organ function\n\nFor Part 2 Dose Expansion:\n\n* Subjects must have at least 4 cycles of platinum-based chemotherapy in 2L and have Complete Response, Partial Response, or Stable Disease\n* Subjects must have progressed while on a PARP inhibitor for 1L maintenance Additional protocol-defined inclusion criteria may apply\n\nEXCLUSION CRITERIA:\n\n* Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor.\n* Subjects with carcinosarcomas (even if there is a serous component)\n* A serious illness or medical condition(s)\n* Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.\n\nAdditional protocol-defined exclusion criteria may apply",{"count":484,"type":21},172,[72],"This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.",[488,35,36,489],"Solid Tumor","Peritoneal Cancer",[488],"2026-04-01",{"date":493,"type":52},"2026-04-07",{"date":495,"type":52},"2020-10-26",{"date":497,"type":21},"2028-06-30",{"name":499,"class":116},"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",24,{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":98,"minAge":18,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":522,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":533},"100546483","phase-1-a-study-of-parg-inhibitor-etx-19477-in-patients-with-advanced-solid-malignancies-100546483","NCT06395519","A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","ERADIC8","Inclusion Criteria:\n\n* Males and females of age ≥ 18 years at the time of signing the informed consent document.\n* Histologically or cytologically confirmed advanced (incurable recurrent, unresectable, or metastatic) solid cancer, excluding primary central nervous system (CNS) tumors.\n* Any solid tumor malignancy, excluding primary CNS tumors, with progression on or after or intolerance to most recent systemic therapy. Preferential enrollment consideration will be made for patients with known BRCA2 mutations resulting in loss of function.\n* Measurable disease per RECIST v1.1.\n* ECOG performance status 0-1.\n* Progression on or after or intolerance to most recent systemic therapy. Prior treatment in the recurrent\u002Fmetastatic setting; patients must have received approved standard therapy that is available to the patient that is known to confer clinical benefit, unless this therapy is contraindicated, intolerable to the patient, or is declined by the patient.\n* No investigational agent within 3 weeks or 5 half-lives (whichever is shorter; minimum of 2 weeks) prior to first dose of study drug.\n* Life expectancy of at least 3 months.\n\nExclusion Criteria:\n\n* Receiving continuous corticosteroids at prednisone-equivalent dose of \\>10 mg\u002Fday. Chronic systemic corticosteroid therapy for physiologic replacement (≤10 mg\u002Fday of prednisone equivalents) and the use of non-systemic corticosteroids (e.g., inhaled, topical, intra-nasal, intra-articular, or ophthalmic) are permitted.\n* Definitive radiotherapy within 6 weeks and palliative radiation within 2 weeks prior to the first dose of study drug.\n* Symptomatic untreated or progressing brain metastases. Stable, treated brain metastases are allowed if no evidence of radiologic or clinical progression or increasing corticosteroid use for at least 4 weeks.\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of ETX-19477 and no history of bowel obstruction within 6 months and\u002For peritoneal fluid drainage within 8 weeks prior to the first dose of study drug.\n* Known symptomatic and radiologically progressing or leptomeningeal disease (LMD). If LMD has been reported radiographically on baseline magnetic resonance imaging (MRI), but is not suspected clinically by the Investigator, the patient must be free of neurological symptoms of LMD.\n* Resting ECG with QT interval calculated using the Fridericia's formula (QTcF) \\>470 msec on 2 or more timepoints within a 24-hour period, or history or family history of congenital long QT syndrome, or taking concomitant medications that are known to prolong the QT\u002FQTc interval, or history of additional risk factors for torsades de pointes (Tdp).\n* History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, clinically significant uncontrolled arrhythmias, or any history of symptomatic congestive heart failure.\n* Known active or chronic infection (viral, bacterial, or fungal), including tuberculosis, hepatitis B, hepatitis C, or AIDS-related illness. Controlled infections, including HIV and \"cured\" hepatitis C (no active fever, no evidence of systemic inflammatory response syndrome) that are stable with undetectable viral load on antiviral treatment are not exclusionary.\n* Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per Investigator assessment).\n* Known other previous\u002Fcurrent malignancy requiring treatment within ≤2 years except for limited disease treated with curative intent, such as carcinoma in situ, squamous or basal cell skin carcinoma, or superficial bladder carcinoma and not requiring ongoing chemotherapy.\n* Patients receiving proton pump inhibitors (PPIs), strong cytochrome P450 (CYP)3A inhibitors and inducers, or P-glycoprotein (P-gp) inhibitors. Patients should not receive PPIs within 7 days prior to first dose of study drug. Strong CYP3A inducers or inhibitors or strong P-gp inhibitors should not be given within 6 half-lives prior to first dose of study drug.\n* Patients currently treated with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants",{"count":509,"type":21},120,[72,153],"This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.",[513,514,27,515,35,516,517,518,519,520,521,156,157],"Advanced or Metastatic Solid Tumors","Breast Cancer","Prostate Cancer","BRCA2 Mutation","ER+ Breast Cancer","Castrate Resistant Prostate Cancer","BRCA1 Mutation","BRCA Mutation","Endometrial Cancer",[523],"PARG Inhibitor","2026-03-24",{"date":526,"type":52},"2026-03-27",{"date":528,"type":52},"2024-05-13",{"date":530,"type":21},"2026-12",{"name":532,"class":116},"858 Therapeutics, Inc.",14,{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":540,"targetDuration":4,"studyType":22,"phases":542,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":90},"100631032","single-arm-prospective-clinical-trial-of-efficacy-and-safety-of-daphnetin-capsules-combined-with-tc-regimen-for-targeted-maintenance-therapy-after-initial-treatment-of-stage-iii-iv-epithelial-ovarian-cancer-ror1-100631032","NCT07495397","Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO\u002FR1)","Inclusion Criteria:\n\n* Inclusion Criteria:\n\n  1. Patients with stage III-IV treatment-naïve ovarian cancer aged 18 to 75 years (including cut-off values) who have completed satisfactory tumor cytoreductive surgery (R0+R1);\n  2. Voluntarily sign the informed consent form;\n  3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n  4. Expected survival ≥ 12 weeks as assessed by the investigator;\n  5. Adequate organ and bone marrow reserve.\n  6. Willing to provide previous archival or fresh tumor tissue samples (if there is no previous archived tumor tissue, and the investigator assesses that the patient has a high risk of re-retrieving the primary or metastatic part of the tumor tissue specimen is exempted);\n  7. Able to understand the requirements of the trial, willing and able to comply with the trial and follow-up procedures.\n\nExclusion Criteria:\n\n* Exclusion Criteria: Those who meet any of the following conditions cannot be admitted to this trial:\n\n  1. With bleeding tendency PT≥15s or platelet count \\\u003C90×109\u002FL or plasma fibrinogen ≤ 1.6g\u002FL;\n  2. with pulmonary artery embolism, inferior vena cava thrombosis;\n  3. Primary central nervous system tumors or symptomatic central nervous system metastases, meningeal metastases or previous history of epilepsy. Patients with asymptomatic clinical control or central nervous system metastases that are symptomatic but judged stable by the investigator can be included, but the following conditions must be met at the same time: a. 4 weeks from stable clinical symptoms before the first dose≥ b. No evidence of progression of central nervous system disease with enhanced cranial MRI within 4 weeks prior to the first dose; c. Antiepileptic drugs, prednisone dosage ≤10mg\u002Fday or equivalent dose of hormones have been discontinued ≥ 2 weeks before the first dose;\n  4. Other active malignancy within 5 years prior to the first dose. Except for locally cured tumors (e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or carcinoma in situ of the breast, etc.);\n  5. The following cardiovascular disease occurred within 6 months prior to the first dose: symptomatic heart failure with New York Heart Association Class (NYHA) of grade 2 or higher, left ventricular ejection fraction (LVEF) \\\u003C50%, unstable arrhythmia or unstable angina, myocardial infarction requiring treatment, pulmonary embolism, uncontrolled hypertension (This protocol is defined as post-treatment systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg despite optimal antihypertensive therapy , and the investigator assesses that it is clinically significant);\n  6. Have any other disease, physical examination or laboratory test results that make the use of the study drug unsuitable according to the investigator's judgment;\n  7. Patients with chronic oral vitamin K disease are combined\n  8. Subjects with untreated or under treatment for tuberculosis, including but not limited to pulmonary tuberculosis; Those who have received standardized anti-tuberculosis treatment and have been confirmed to be cured by the investigator can be included;\n  9. Serious infection within 4 weeks or active infection within 2 weeks before the first dose;\n  10. Those with the following diseases: human immunodeficiency virus (HIV) infection; Active hepatitis B virus infection \\[positive hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) test \\>200 IU\u002Fml or 103 copies\u002Fml\\]; Hepatitis C virus infected \\[positive HCV antibody and viral ribonucleic acid (HCV-RNA) test results\\]; Treponema pallidum antibody positive and RPR positive;\n  11. Known hypersensitivity or delayed allergic reaction to any component of the study drug;\n  12. Known history of psychotropic, drug abuse, alcohol or drug abuse that affects the test results; Estimated insufficient compliance of patients to participate in this clinical study or having other factors that are considered unsuitable for participation in this study in the opinion of the investigator.",{"count":541,"type":21},98,[24],"Imaging evaluation was performed every 3 months (± 7 days) from enrollment, and real-time examination was performed if new lesions were suspected.\n\nThe study was divided into two parts:\n\nPart 1: Rexiacin capsules assist in the treatment phase of the TC regimen. Part 2: Rexiacin capsule combined with targeted drug maintenance therapy after the end of chemotherapy.\n\nThe overall research cycle is roughly divided into screening period, treatment period, and follow-up period:\n\nScreening period: -7d\\~0d, that is, after the signing of the informed consent form, the screening assessment must be completed within 7 days; Treatment period: 1 dosing cycle every 3 weeks; During chemotherapy, blood routine, liver and kidney function tests were performed every week, tumor marker monitoring and safety evaluation were performed every cycle, and imaging evaluations were performed every 3 months (± 7 days) to evaluate the efficacy. After the end of chemotherapy, the maintenance treatment period and follow-up stage will be conducted, and biochemical tests such as tumor markers, blood routine, liver and kidney function will be performed every 3 months (± 7 days), and imaging evaluation will be performed to evaluate the efficacy, and the patient's self-evaluation results will be evaluated (FOSI, EQ-5D-5L). Peripheral blood immune indicators: Peripheral blood TBNK+Treg lymphocyte subset typing and activated lymphocyte cytokines were performed every 6 months (± 7 days) to monitor the patient's immune status. Medication is administered until an event that meets the criteria for treatment termination occurs or the clinical trial is closed.\n\nClinical tumor imaging evaluation was completed (the evaluation method was consistent before and after, enhanced CT or enhanced MRI was preferred). Investigational drug treatment should be continued until the occurrence of disease progression, or withdrawal due to intolerable toxicity, or receipt of new anti-tumor therapy, or withdrawal of informed consent and voluntary withdrawal for other reasons, or study termination, whichever occurs first. The termination time of the study is the last subject who has received the study drug for 1 year or all subjects are out of the group, whichever is achieved first.\n\nFollow-up period: If the investigator decides to end the subject's treatment with the study drug, then the treatment period will be considered the end of (End of Therapy, EOT). All subjects, including those who discontinue treatment for any reason (except for loss to follow-up, death, withdrawal of informed consent), will have an EOT visit scheduled within 7 days after the investigator decides to end the subject's treatment with study drug. The EOT visit should include vital signs, physical examination, laboratory tests, and clinical tumor imaging evaluation (first enhanced CT or enhanced MRI).\n\nSafety follow-up: Subjects are required to have a safety visit 30 days (+7 days) after the last dose. If the subject plans to receive a new anti-tumor treatment within 30 days after the last dose, a safety follow-up will be conducted before receiving the new anti-tumor therapy. Safety visits are required at the study center and should be performed to assess for AEs, concomitant medications, and concomitant treatments. Until adverse reactions related to the study drug disappear, or drop to Grade ≤1, or return to baseline levels, or stable or acceptable levels assessed by the investigator.\n\nSurvival follow-up: After the safety follow-up, subjects will be followed up for survival once every 3 months (± 7 days), and will be followed up by telephone until death, loss to follow-up, withdrawal of informed consent, or termination of the study.",[35],"2026-03-21",{"date":526,"type":52},{"date":548,"type":52},"2025-11-01",{"date":550,"type":21},"2028-06-01",{"name":552,"class":59},"The First Hospital of Jilin University",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":98,"minAge":560,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":567,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":90},"100547787","phase-1-prehabilitation-for-eoc-fallopian-tube-primary-peritoneal-carcinoma-and-pancreatic-cancer-w-nact-100547787","NCT06412510","Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w\u002F NACT","Prehabilitation for Elderly Patients With Advanced Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Age 65 and older\n* Patients with diagnosis of advanced (Stage III or IV) epithelial ovarian, fallopian tube, or\n* Patients with diagnosis of pancreatic adenocarcinoma (PDAC) (Stage I, II, or III) undergoing neoadjuvant chemotherapy.\n* Patients with locally advanced esophageal cancer undergoing neoadjuvant chemotherapy.\n* Patients with locally advanced muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.\n\nExclusion Criteria:\n\n* Life expectancy less than 3 months in the opinion of the treating physician\n* Patients unable to provide informed consent.\n* Wheelchair bound patients\u002F physical immobility.\n* Severe cardiopulmonary disease defined as NYHA class III or IV\n* Patients with malignant bowel obstruction who will require surgical intervention or nutritional support in the form of enteral or parenteral nutrition will also be excluded.\n* Patients with any other comorbidity or condition, which, in the opinion of the enrolling investigator, would place the patient at unnecessarily higher greater risk or burden, or participating in the study would not be in the best interests of the patient.","65 Years",{"count":562,"type":21},22,[72,153],"The purpose of this study is to see whether participants who are assigned to a multimodal prehabilitation intervention during chemotherapy are able to adhere with exercise and nutrition program to prepare for their cancer surgery.",[27,35,566],"Pancreatic Adenocarcinoma",[27,421],"2026-03-16",{"date":570,"type":52},"2026-03-18",{"date":572,"type":52},"2025-09-05",{"date":574,"type":21},"2026-09",{"name":142,"class":59},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":269,"acronym":270,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":582,"targetDuration":4,"studyType":22,"phases":583,"briefSummary":275,"conditions":584,"keywords":585,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":90},"100629921","phase-1-dual-targeting-car-nk-cells-for-recurrent-ovarian-cancer-msln-fr-muc16-100629921","NCT07480954","Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","Inclusion Criteria:\n\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (high-grade serous preferred).\n* Recurrent or refractory disease after at least 2 prior systemic treatment lines (including a platinum-based regimen unless contraindicated).\n* Measurable disease per RECIST v1.1.\n* Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125) (archival or fresh biopsy).\n* ECOG performance status 0-1.\n* Adequate organ function (example): ANC \\>= 1.0 x 10\\^9\u002FL; platelets \\>= 75 x 10\\^9\u002FL; hemoglobin \\>= 8 g\u002FdL; AST\u002FALT \\\u003C= 3 x ULN (\\\u003C= 5 x ULN with liver metastases); total bilirubin \\\u003C= 1.5 x ULN; creatinine clearance \\>= 50 mL\u002Fmin.\n* Negative pregnancy test for women of childbearing potential; agreement to use effective contraception through 12 months post-infusion (or per local gene-therapy guidance).\n* Able to comply with study procedures and follow-up schedule; written informed consent.\n\nExclusion Criteria:\n\n* Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or any prior therapy directed to the same target, per protocol).\n* Active central nervous system (CNS) metastases or carcinomatous meningitis requiring therapy.\n* Uncontrolled infection, including active tuberculosis; or clinically significant, uncontrolled viral infection.\n* Known HIV infection with uncontrolled viremia; active hepatitis B or hepatitis C with detectable viral load (testing required at screening).\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA Class III\u002FIV heart failure).\n* Active autoimmune disease requiring systemic immunosuppression within 30 days (physiologic steroid replacement allowed).\n* Concurrent anti-cancer therapy (chemotherapy, targeted therapy, radiotherapy) not permitted within a protocol-defined washout period.\n* Major surgery within 4 weeks prior to lymphodepletion (except minor procedures).",{"count":273,"type":21},[72,153],[35,40,277,278],[280,281,282,283,586,285,286,78],"MUC16 (CA 125)","2026-03-14",{"date":570,"type":52},{"date":590,"type":52},"2026-02-04",{"date":592,"type":21},"2028-05-17",{"name":294,"class":116},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":603,"phases":4,"briefSummary":604,"conditions":605,"keywords":606,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":90},"100351962","determining-prognostic-immune-markers-in-patients-with-ovarian-cancer-100351962","NCT03862677","Determining Prognostic Immune Markers in Patients With Ovarian Cancer","IMPrOVE","Inclusion Criteria:\n\n* Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and\u002For immunotherapy.\n* Age ≥18 years.\n* WHO performance status 0-2.\n* Accessible for treatment and follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.\n* Any known severe infection like HIV, hepatitis A, B and C.\n* Receiving immune suppressive treatment.\n* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.",{"count":602,"type":21},300,"OBSERVATIONAL","The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).",[35],[311,312,313,607,608,599,609,610],"EOC","Immunity","Prognostic","Immune markers","2026-02-12",{"date":613,"type":52},"2026-02-13",{"date":615,"type":52},"2020-08-15",{"date":617,"type":21},"2027-01-31",{"name":619,"class":59},"Leiden University Medical Center",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":627,"targetDuration":4,"studyType":22,"phases":628,"briefSummary":629,"conditions":630,"keywords":631,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":644},"100552145","phase-1-a-study-to-learn-if-27t51-a-mucin-16-muc16-protein-targeting-immune-cell-therapy-administered-alone-or-in-combination-is-safe-and-how-well-it-works-for-adult-participants-with-recurrent-or-treatment-resistant-ovarian-cancers-100552145","NCT06469281","A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers","A Phase 1a\u002F1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Key Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n2. Histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer according to World of Health Organization (WHO) 2020 classification\n3. Recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer, as described in the protocol\n4. Serum cancer antigen (CA) 125 ≥ 2 × upper limit of normal (ULN) as assessed at the local lab by a 510(k) cleared test at screening\n5. Participants must have at least 1 measurable tumor lesion as defined by the response evaluation criteria in solid tumors (RECIST) 1.1.\n6. Expected survival ≥ 3 months\n\nKey Exclusion Criteria:\n\n1. Inadequate cardiovascular, renal and hepatic function, as described in the protocol\n2. Absolute lymphocyte count (ALC) \\\u003C 100 cells\u002FμL at time of leukapheresis\n3. History of Grade ≥ 2 hemorrhage within 30 days, or inadequate coagulation parameters, as described in the protocol\n4. Known history or presence of clinically relevant central nervous system (CNS) pathology, as described in the protocol\n5. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune related adverse events (AEs)\n6. Treatment with any cellular or gene therapy\n\nNote: Other protocol-defined Inclusion\u002FExclusion criteria apply",{"count":441,"type":21},[72],"This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer.\n\nThis study has two (2) major parts:\n\nPhase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51.\n\nInformation collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.",[35,40,36],[27,632,633,634,284,396],"CAR T","Peritoneal","Fallopian Tube","2026-01-30",{"date":637,"type":52},"2026-02-03",{"date":639,"type":52},"2024-08-06",{"date":641,"type":21},"2030-05-27",{"name":643,"class":116},"Regeneron Pharmaceuticals",5,{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":22,"phases":655,"briefSummary":656,"conditions":657,"keywords":658,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":667,"locationsCount":669},"100609763","phase-3-azd5335-vs-mirvetuximab-soravtansine-in-fr-high-and-azd5335-vs-chemotherapy-in-fr-low-platinum-resistant-ovarian-cancer-100609763","NCT07218809","AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)","TREVI-OC-01","Key Inclusion criteria\n\n* Participants with confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.\n* Participants must have platinum-resistant disease:\n* Participants who have only had one prior line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between \\> 3 months and ≤ 6 months after the date of the last dose of platinum.\n* Participants who have received 2 or 3 lines of platinum therapy must have progressed ≤ 6 months after the date of the last dose of platinum.\n* Participants must have radiologically progressed on or after their most recent line of therapy.\n* Participants must have received at least one, but no more than 3, prior systemic lines of anti-cancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment\n* Participants with documented BRCA mutation (germline and\u002For somatic) must have received prior PARPi if the participant is eligible per approved label and standard-of-care institutional guidelines, except in cases of documented contraindication, precaution or intolerance.\n* Provision of an FFPE tumour tissue sample\n\nKey Exclusion criteria\n\n* Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumours containing any of the above histologies, or low-grade or borderline ovarian tumour.\n* Primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤ 3 months after the last dose of first line platinum-containing chemotherapy.\n* Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment\u002Fmonitoring\n* Current signs, symptoms, or clinical investigations consistent with bowel obstruction, including sub-occlusive disease.\n* Participant has non-infectious ILD\u002Fpneumonitis or has a history of non-infectious ILD\u002Fpneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n* Prior treatment with any FRα-targeted therapy, including MIRV, or any TOP1i ADC.\n* Major surgical procedure within 4 weeks of the first dose of study intervention",{"count":654,"type":21},1100,[103],"The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.",[35],[35,489,659,660],"Follopian Tube Cancer","Platinum Resistant Ovarian Cancer","2026-01-15",{"date":663,"type":52},"2026-01-16",{"date":665,"type":52},"2025-12-29",{"date":641,"type":21},{"name":668,"class":116},"AstraZeneca",125,{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":4,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":677,"targetDuration":4,"studyType":22,"phases":679,"briefSummary":680,"conditions":681,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":690,"locationsCount":202},"100569171","phase-2-catalina-2-a-clinical-study-of-torl-1-23-in-platinum-resistant-ovarian-cancer-100569171","NCT06690775","CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all the following criteria apply:\n\n1. Females ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the informed consent.\n2. Participants must sign the informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n3. Disease Type:\n\n   * Histologically or cytologically confirmed diagnosis of advanced (unresectable) or metastatic high grade serous ovarian, primary peritoneal (i.e, of primary origin), or fallopian tube cancer. High-grade endometrioid ovarian cancer is permitted for enrollment.\n   * Participant's tumor must be positive for CLDN6 expression as defined by the CLDN6 reference laboratory assay. Tumor tissue will be required for submission for CLDN6 testing prior to Cycle 1 Day 1.\n   * Participants must have platinum-resistant disease, defined as the following:\n   * If participants received only 1 line of platinum-based therapy, they must have completed 4 or more cycles of platinum-containing therapy, must have achieved a CR or PR, and progressed \\>3 months but ≤6 months after the last dose of platinum.\n   * Participants who have received more than 1 line of platinum- based therapy must have progressed on or within 6 months after the last dose of platinum.\n   * NOTE: This should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression (per RECIST v1.1).\n   * Participants who are platinum-refractory during front-line treatment are excluded.\n   * Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single- agent therapy is appropriate as the next line of treatment. Study rules for evaluation of number of prior systemic lines of therapy:\n   * Adjuvant ± neoadjuvant is considered one line of therapy\n   * Maintenance therapy (eg, bevacizumab or PARP inhibitors) will be considered part of the preceding line of therapy (ie, not counted independently)\n   * Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)\n   * Hormonal therapy will not be counted as a separate line of therapy\n4. Measurable disease, per RECIST v1.1\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.\n6. Adequate organ function, based on the following laboratory values:\n\n   * ANC: ≥1,500\u002FmcL\n   * Platelets: ≥100,000\u002FmcL without transfusion within 4 weeks of first dose\n   * Hemoglobin: 9 g\u002FdL with transfusion or EPO support up to 14 days before eligibility assessment\n   * Measured or calculated creatinine clearance with a validated formula\\*: ≥30 mL\u002Fmin\n   * Serum total bilirubin: ≤1.5 X ULN (participants with known Gilbert disease or liver metastases who have serum bilirubin level ≤3×ULN may be enrolled\n   * AST (SGOT) and ALT (SGPT): ≤3 X ULN (participants with active liver metastases who have ALT\u002FAST ≤5 X ULN may be enrolled)\n   * Albumin: ≥2.5 g\u002FdL\n   * ECG: 12-Lead ECG with normal tracing or non-clinically significant changes that do not require medical intervention and QTcF interval\n\n     * 470 msec and without history of Torsades des Pointes or other symptomatic QTc abnormality.\n7. Participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug treatment. The serum pregnancy test must be negative for the participant to be eligible.\n8. Participants must agree to use a highly effective birth control method from the time of the first study drug treatment through 7 months after the last study drug treatment, or be of nonchildbearing potential.\n9. Participants must agree not to donate eggs from the first study drug treatment through 7 months after the last study drug treatment.\n10. Participants must agree to not breastfeed from the first dose of study treatment through 90 days after the last dose of study treatment.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Has not recovered \\[recovery is defined as National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade ≤1\\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.\n2. Participants with clear cell, mucinous, sarcomatous (including carcinosarcoma), mixed histology, or low-grade, borderline ovarian tumors or non-epithelial ovarian cancers.\n3. Participants with primary platinum-refractory ovarian, primary peritoneal (i.e. of primary origin) or fallopian tube cancer, defined as disease that did not respond to or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy.\n4. Received prior chemotherapeutic, investigational, radiotherapy, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23. There is no waiting period required for stereotactic radiosurgery.\n5. Prior treatment with a CLDN6-targeting agent or an MMAE-containing ADC.\n6. Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded.\n7. Grade 2 or greater peripheral neuropathy.\n8. History of non-infectious pneumonitis\u002FILD within 6 months of first dose of study drug.\n9. Participants must not be considered a high medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.\n10. History of significant cardiac disease:\n\n    1. Congestive heart failure \\>New York Heart Association class 2 within last year\n    2. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)\n    3. Myocardial infarction less than 6 months before start of study drug\n    4. Anti-arrhythmic therapy (beta blockers are permitted)\n    5. Any unstable ischemic disease or untreated arrhythmia\n11. Known history of myelodysplastic syndrome or acute myeloid leukemia.\n12. History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. Participants with malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ of the breast are not excluded.\n13. Uncontrolled infection; active, clinically serious infections (CTCAE Grade \\>2).\n14. Participants with seizure disorder requiring medication.\n15. Known hypersensitivity or intolerance to any of the study drugs, study drug classes, or excipients in the formulation.\n16. History of having an allogeneic bone marrow or organ transplant.\n17. Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator.\n18. Participants who are taking any drugs that are strong inducers and\u002For strong inhibitors of CYP3A4 enzymes.\n19. Participants who are taking any drugs that are inhibitors of P-glycoprotein.",{"count":678,"type":21},230,[153],"A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.",[35,682,36,683],"Primary Peritoneal","Endometrioid Ovarian Cancer","2025-12-19",{"date":686,"type":52},"2025-12-23",{"date":688,"type":52},"2024-11-20",{"date":429,"type":21},{"name":691,"class":116},"TORL Biotherapeutics, LLC"]